Trials / Unknown
UnknownNCT03260179
Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810
An Open-label Phase Ib, Study, to Determine Safety of Oral AL3810 in Patients With Locally Advanced or Metastatic Gastric, Hepatocellular or Nasopharyngeal Carcinoma
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Haihe Biopharma Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This project intends to make a study of personalized medicine evaluation system establishment for liver cancer, gastric cancer and nasopharynx cancer to provide strong support for the development of Precision Medicine and personalized medicine for the patients of high-incidence-rates cancer in China.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AL3810 | Fasting，oral ，4w on or 3w on/1w off |
| DRUG | AL3810 | Fasting，oral ，4w on or 3w on/1w off |
| DRUG | AL3810 | Fasting，oral ，4w on or 3w on/1w off |
Timeline
- Start date
- 2017-08-31
- Primary completion
- 2019-01-31
- Completion
- 2019-06-30
- First posted
- 2017-08-24
- Last updated
- 2017-08-24
Locations
7 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03260179. Inclusion in this directory is not an endorsement.